flow trial semaglutide kidney outcomes results 2024 🚨 Journal Club: Review 🚨 The FLOW Trial, published in The New England Journal of Medicine (May 2024), evaluated the effects of on disease in patients with type Long-term kidney outcomes of semaglutide

The medication works in the background without requiring constant management

Not eating enough will cause the bodys metabolism to shut down and switch to fat-storage mode, which is the last thing most GLP-1 patients want

After absorption, the pharmacokinetic properties and effects of semaglutide are similar, irrespective of the route of administration (103)

These bloated cells become resistant to insulin, which helps break down glucose, and trigger inflammation that can cause tissue damage

Retatrutides glucagon receptor activation mobilizes stored fat from the liver and adipose tissue, essentially freeing fatty acids into the bloodstream